Winkler Izabela, Gogacz Marek, Rechberger Tomasz
II Katedra I Klinika Ginekologii UM w Lublinie.
Ginekol Pol. 2012 Apr;83(4):295-300.
Ovarian cancer is the sixth most common cancer in women worldwide and remains the leading cause of death due to gynecologic tumors. Bad prognosis is caused by advanced-stage high-grade disease. To reduce mortality and improve outcomes in this type of cancer researchers attempt to introduce new therapies based on genetic engineering or immunotherapy Th17 lymphocytes belong to the helper T cell population. These cells arise from immature CD4 + lymphocytes in the presence of IL-6 and TGF-beta. Produce IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-6, TNF-alpha. Interleukin-17 and Th17 cells play an active role in inflammation and autoimmune diseases. The existence of these cells was confirmed in different types of cancer. However the exact role of IL-17 in tumor immunopathogenesis remains undefined. It has been reported that expression of interleukin-17 in tumor cells suppresses tumor progression through enhanced antitumor immunity or promotes tumor progression through an increase in inflammatory angiogenesis.
卵巢癌是全球女性中第六大常见癌症,仍是妇科肿瘤的主要死因。晚期高级别疾病导致预后不良。为了降低这种癌症的死亡率并改善治疗结果,研究人员试图引入基于基因工程或免疫疗法的新疗法。Th17淋巴细胞属于辅助性T细胞群体。这些细胞在IL-6和转化生长因子-β存在的情况下从不成熟的CD4 +淋巴细胞分化而来。产生IL-17A、IL-17F、IL-21、IL-22、IL-26、IL-6、肿瘤坏死因子-α。白细胞介素-17和Th17细胞在炎症和自身免疫性疾病中发挥积极作用。这些细胞在不同类型的癌症中均被证实存在。然而,IL-17在肿瘤免疫发病机制中的确切作用仍不明确。据报道,肿瘤细胞中白细胞介素-17的表达可通过增强抗肿瘤免疫力抑制肿瘤进展,或通过增加炎性血管生成促进肿瘤进展。